Ali Bhatt

Ali Bhatt has advanced the systematic mapping of histone modification landscapes in cancer through high-throughput ChIP-seq approaches, revealing how combinatorial histone mark patterns distinguish active enhancers, poised promoters, and repressed chromatin domains in tumor cells versus normal tissue. His laboratory has identified cancer-specific enhancer activation signatures defined by H3K27ac and H3K4me1 that predict oncogene dependencies and therapeutic vulnerabilities. He has contributed to understanding how global histone modification reprogramming accompanies tumor initiation and progression. His computational and experimental approaches integrate histone epigenomics with gene expression and DNA methylation data for comprehensive cancer epigenome characterization.